New combo therapy aims to outsmart resistant lung cancer

NCT ID NCT05401110

Recruiting now Disease control Sponsor: Karen Reckamp, MD, MS Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 28 times

Summary

This early-phase study tests whether adding carotuximab to the standard drug osimertinib is safe and tolerable for people with advanced EGFR-mutated non-small cell lung cancer. About 60 participants whose cancer has worsened on previous treatments will receive the combination. The main goal is to find the best dose and watch for side effects, while also tracking how well the tumors respond.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Cedars-Sinai Cancer at Beverly Hills (THO)
RECRUITING

Beverly Hills, California, 90211, United States

Contact
Cedars-Sinai Cancer at Hunt Cancer Center - TMPNCC
RECRUITING

Torrance, California, 90505, United States

Contact
Cedars-Sinai Cancer at SOCC
RECRUITING

Los Angeles, California, 90048, United States

Contact
Cedars-Sinai Cancer at The Angeles Clinic and Research Institute
RECRUITING

Los Angeles, California, 90025, United States

Contact
Cedars-Sinai Medical Center
RECRUITING

Los Angeles, California, 90048, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

LUNG CANCER NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER